Author:
Conde-Estévez David,Grau Santiago,Alvarez-Lerma Francisco
Reference7 articles.
1. FDA. FDA Drug Safety Communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. [consultado 20 sep 2011]; Disponible en: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm
2. EMA. Questions and answers on the review of Tygacil (tigecycline). EMA [consultado 20 Sep 2011]. Disponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000644/human_med_001118.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125&jsenabled=true#
3. Off-label prescription of tigecycline: clinical and microbiological characteristics and outcomes;Conde-Estévez;Int J Antimicrob Agents,2010
4. Antimicrobial Susceptibilities of a Worldwide Collection of Stenotrophomonas maltophilia Isolates Tested against Tigecycline and Agents Commonly Used for S maltophilia Infections;Farrell;Antimicrob Agents Chemother,2010
5. Factors associated with adherence to guidelines for the use of tigecycline in a tertiary care hospital;Grau;J Chemother,2010